| 1 |
35573877 | Time-course monitoring of in vitro biotransformation reaction via solid-phase microextraction-ambient mass spectrometry approaches. | 2022 Feb |
2 |
| 2 |
33043592 | Poly(L-Glutamic Acid)-Drug Conjugates for Chemo- and Photodynamic Combination Therapy. | 2021 Jan |
1 |
| 3 |
33933077 | Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma. | 2021 May 1 |
1 |
| 4 |
31951366 | Positioning Remodeling Nanogels Mediated Codelivery of Antivascular Drug and Autophagy Inhibitor for Cooperative Tumor Therapy. | 2020 Feb 12 |
1 |
| 5 |
32243160 | Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. | 2020 May 22 |
1 |
| 6 |
33016266 | Two new polymorphic forms of combretastatin A-4, an antitumour agent. | 2020 Oct 1 |
1 |
| 7 |
30525602 | 1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin-Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation. | 2019 Feb 28 |
1 |
| 8 |
32104392 | Combretastatin A4/poly(L-glutamic acid)-graft-PEG conjugates self-assembled to nanoparticles. | 2018 Mar |
1 |
| 9 |
26503632 | Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog. | 2016 Jan 7 |
1 |
| 10 |
27407030 | Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles. | 2016 Sep 15 |
1 |
| 11 |
32262957 | Reverse micelles-in-microspheres with sustained release of water-soluble combretastatin A4 phosphate for S180 tumor treatment. | 2016 Jan 28 |
1 |
| 12 |
26426829 | A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics. | 2015 Nov 2 |
1 |
| 13 |
23232969 | Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro. | 2013 Feb |
1 |
| 14 |
23810282 | Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity. | 2013 Aug 15 |
1 |
| 15 |
20699436 | The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. | 2010 Nov |
1 |
| 16 |
19135763 | A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4. | 2009 Jun |
1 |
| 17 |
19377096 | 1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase. | 2009 Jul |
1 |
| 18 |
18074350 | p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. | 2008 Apr 15 |
1 |
| 19 |
17143747 | Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. | 2007 Jan |
1 |
| 20 |
15014350 | Combretastatin A4 phosphate. | 2004 Mar |
1 |
| 21 |
12699742 | Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. | 2003 May 5 |
1 |
| 22 |
12807934 | Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. | 2003 Aug 1 |
1 |
| 23 |
14645433 | Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. | 2003 Dec 1 |
2 |
| 24 |
11259100 | Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. | 2001 Mar 23 |
1 |